

SEQUENCE LISTING

<110> Boehringer Ingelheim Pharma KG

<120> Method for identifying substances which positively influence inflammatory conditions

<130> 1/1179

<140>

<141>

<150> US 60/257,856

<151> 2000-12-22

<160> 8

<170> PatentIn Ver. 2.1

<210> 1

<211> 63

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 1

```
ggccagtga  ttgtaatacg  actcactata  gggaggcggt  tttttttttt  tttttttttt  60
ttt                                             63
```

<210> 2

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 2

```
gtcgtcaaga  tgctaccgtt  cagga                                             25
```

<210> 3

<211> 802

<212> DNA

<213> Homo sapiens

<400> 3

```
ggagggccgg  gcaccgcggc  atggaggggtc  aacgctggct  gccgctggag  gccaatcccg  60
aggtcaccaa  ccagtttctt  aaacaattag  gtctacatcc  taactggcaa  ttcgttgatg  120
tatatggaat  ggatcctgaa  ctccttagca  tggtagcaag  accagtctgt  gcagtcttac  180
ttctctttcc  tattacagaa  aagtatgaag  tattcagaac  agaagaggaa  gaaaaaataa  240
aatctcaggg  acaagatggt  acatcatcag  tatatttcat  gaagcaaaca  atcagcaatg  300
cctgtggaac  aattggactg  attcatgcta  ttgcaaacaa  taaagacaag  atgcactttg  360
aatctggatc  aaccttgaaa  aaattcctgg  aggaatctgt  gtcaatgagc  cctgaagaac  420
```

```

gagccagata cctggagaac tatgatgcca tccgagttac tcatgagacc agtgcccatg 480
aaggtcagac tgaggcacca agtatagatg agaaagtaga tcttcatttt attgcattag 540
ttcatgtaga tgggcatctc tatgaattag atgggcggaa gccattttcca attaaccatg 600
gtgaaactag tgatgaaact ttattagagg atgccataga agtttgcaag aagtttatgg 660
agcgcgaccc tgatgaacta agatttaatg cgattgctct ttctgcagca tagcttgtca 720
ataatggaaa caccaaaaac tgtattattt gcaactaaat tttctctgcc catacactaa 780
ctcaaaaatt ttgatatttt cc 802

```

```

<210> 4
<211> 230
<212> PRT
<213> Homo sapiens

```

```

<400> 4
Met Glu Gly Gln Arg Trp Leu Pro Leu Glu Ala Asn Pro Glu Val Thr
  1              5              10              15
Asn Gln Phe Leu Lys Gln Leu Gly Leu His Pro Asn Trp Gln Phe Val
      20              25              30
Asp Val Tyr Gly Met Asp Pro Glu Leu Leu Ser Met Val Pro Arg Pro
      35              40              45
Val Cys Ala Val Leu Leu Leu Phe Pro Ile Thr Glu Lys Tyr Glu Val
      50              55              60
Phe Arg Thr Glu Glu Glu Glu Lys Ile Lys Ser Gln Gly Gln Asp Val
      65              70              75              80
Thr Ser Ser Val Tyr Phe Met Lys Gln Thr Ile Ser Asn Ala Cys Gly
      85              90              95
Thr Ile Gly Leu Ile His Ala Ile Ala Asn Asn Lys Asp Lys Met His
      100             105             110
Phe Glu Ser Gly Ser Thr Leu Lys Lys Phe Leu Glu Glu Ser Val Ser
      115             120             125
Met Ser Pro Glu Glu Arg Ala Arg Tyr Leu Glu Asn Tyr Asp Ala Ile
      130             135             140
Arg Val Thr His Glu Thr Ser Ala His Glu Gly Gln Thr Glu Ala Pro
      145             150             155             160
Ser Ile Asp Glu Lys Val Asp Leu His Phe Ile Ala Leu Val His Val
      165             170             175
Asp Gly His Leu Tyr Glu Leu Asp Gly Arg Lys Pro Phe Pro Ile Asn
      180             185             190
His Gly Glu Thr Ser Asp Glu Thr Leu Leu Glu Asp Ala Ile Glu Val
      195             200             205
Cys Lys Lys Phe Met Glu Arg Asp Pro Asp Glu Leu Arg Phe Asn Ala
      210             215             220

```

Ile Ala Leu Ser Ala Ala
225 230

<210> 5
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 5
ggggacaagt ttgtacaaaa aagcaggcta tggagggtca acgctggctg 50

<210> 6
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 6
ggggaccact ttgtacaaga aagctgggtc tatgctgcag aaagagcaat 50

<210> 7
<211> 866
<212> DNA
<213> Homo sapiens

<400> 7
atggcgaggc gcggttacag cttttcgctg actacattca gcccgctctgg taaacttgtc 60
cagattgaat atgctttggc tgctgtagct ggaggagccc cgtccgtggg aattaaagct 120
gcaaagtgtg tggattagc aactgagaaa aaacagaaat ccattctgta tgatgagcga 180
ccgattaca agtagaacc aattaccaag catatagggt tgggtgtacag tggcatgggc 240
taccaagaac ccattcctac agctcagctg gtacagagag tagcttctgt gatgcaagaa 360
tatactcagt cagggtgggtg tcgtccattt ggagtttctt tacttatttg tggttggaat 420
gagggacgac catattttatt tcagtcagat ccactctggag cttactttgc ctggaaaagct 480
acagcaatgg gaaagaacta tgtgaatggg aagactttcc ttgagaaaag atataatgaa 540
gatctggaac ttgaagatgc cattcataca gccatcttaa ccctaaagga aagctttgaa 600
gggcaaataa cagaggataa catagaagtt ggaatctgca atgaagctgg atttaggagg 660
cttactccaa ctgaagttaa ggattacttg gctgccatag cataacaatg aagtgactga 720
aaaatccaga atttcagata atctatctac ttaaacaatg ttaaagtatg ttttgttttg 780
cagacttttt gcatacttat ttctacatgg tttaaatcga ctgtttttta aatgacactt 840
ataaatccta ataaactgtt aaaccc 866

<210> 8
<211> 234
<212> PRT
<213> Homo sapiens

<400> 8

TOGETHER "DECEMBER"

Met	Ala	Glu	Arg	Gly	Tyr	Ser	Phe	Ser	Leu	Thr	Thr	Phe	Ser	Pro	Ser	1	5	10	15
Gly	Lys	Leu	Val	Gln	Ile	Glu	Tyr	Ala	Leu	Ala	Ala	Val	Ala	Gly	Gly	20	25	30	
Ala	Pro	Ser	Val	Gly	Ile	Lys	Ala	Ala	Asn	Gly	Val	Val	Leu	Ala	Thr	35	40	45	
Glu	Lys	Lys	Gln	Lys	Ser	Ile	Leu	Tyr	Asp	Glu	Arg	Ser	Val	His	Lys	50	55	60	
Val	Glu	Pro	Ile	Thr	Lys	His	Ile	Gly	Leu	Val	Tyr	Ser	Gly	Met	Gly	65	70	75	80
Pro	Asp	Tyr	Arg	Val	Leu	Val	His	Arg	Ala	Arg	Lys	Leu	Ala	Gln	Gln	85	90	95	
Tyr	Tyr	Leu	Val	Tyr	Gln	Glu	Pro	Ile	Pro	Thr	Ala	Gln	Leu	Val	Gln	100	105	110	
Arg	Val	Ala	Ser	Val	Met	Gln	Glu	Tyr	Thr	Gln	Ser	Gly	Gly	Val	Arg	115	120	125	
Pro	Phe	Gly	Val	Ser	Leu	Leu	Ile	Cys	Gly	Trp	Asn	Glu	Gly	Arg	Pro	130	135	140	
Tyr	Leu	Phe	Gln	Ser	Asp	Pro	Ser	Gly	Ala	Tyr	Phe	Ala	Trp	Lys	Ala	145	150	155	160
Thr	Ala	Met	Gly	Lys	Asn	Tyr	Val	Asn	Gly	Lys	Thr	Phe	Leu	Glu	Lys	165	170	175	
Arg	Tyr	Asn	Glu	Asp	Leu	Glu	Leu	Glu	Asp	Ala	Ile	His	Thr	Ala	Ile	180	185	190	
Leu	Thr	Leu	Lys	Glu	Ser	Phe	Glu	Gly	Gln	Met	Thr	Glu	Asp	Asn	Ile	195	200	205	
Glu	Val	Gly	Ile	Cys	Asn	Glu	Ala	Gly	Phe	Arg	Arg	Leu	Thr	Pro	Thr	210	215	220	
Glu	Val	Lys	Asp	Tyr	Leu	Ala	Ala	Ile	Ala	225	230								